TransCode Therapeutics, Inc.
RNAZ
$1.77
-$0.13-6.61%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 14.15% | 25.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -14.99% | 1.23% | |||
| Operating Income | 14.99% | -1.23% | |||
| Income Before Tax | 61.55% | -32.81% | |||
| Income Tax Expenses | -99.87% | 2.30% | |||
| Earnings from Continuing Operations | 62.05% | -32.30% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 62.05% | -32.30% | |||
| EBIT | 14.99% | -1.23% | |||
| EBITDA | 15.04% | -1.53% | |||
| EPS Basic | 66.29% | -29.06% | |||
| Normalized Basic EPS | 13.73% | -19.93% | |||
| EPS Diluted | 66.29% | -29.06% | |||
| Normalized Diluted EPS | 13.73% | -19.93% | |||
| Average Basic Shares Outstanding | 4.38% | 0.43% | |||
| Average Diluted Shares Outstanding | 4.38% | 0.43% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||